SNSS: Summary for Sunesis Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Tuesday, November 24, 2009, 3:17pm EST - Canadian Markets close in 43 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Sunesis Pharmaceuticals Inc. (SNSS)

At 14:49 EST: 0.3078 USD

0.0022 (0.71%)

MORE ON SNSS

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Sunesis Pharmaceuticals, Inc. (NCM:SNSS) Delayed quote data

Last Trade:	0.3078 USD
Trade Time:	2:49PM EST
Change:	0.0022 (0.71%)
Prev Close:	0.31
Open:	0.30
Bid:	0.30 x 4900
Ask:	0.308 x 9100
1y Target Est:	1.00

Day's Range:	0.2802 - 0.318
52wk Range:	0.05 - 1.00
Volume:	354,670
Avg Vol (3m):	313,357
Market Cap:	10.59M
P/E (ttm):	N/A
EPS (ttm):	-2.019
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add SNSS to Portfolio

Download Data

HEADLINES

•	SUNESIS PHARMACEUTICALS INC Financials
	EDGAR Online Financials (Thu, Nov 19)

•	Sunesis Reports Data From Nonclinical Studies of Voreloxin at AACR-EORTC-NCI Conference
	Marketwire (Wed, Nov 18)

•	SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
	EDGAR Online (Tue, Nov 17)

•	New Star Analyst Rankings for Sunesis Pharmaceuticals, Inc.
	StarMine (Tue, Nov 17)

•	SUNESIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 16)

•	Sunesis reports $4.9M loss
	at bizjournals.com (Mon, Nov 16)

•	Sunesis Reports Financial Results for the Third Quarter of 2009
	Marketwire (Mon, Nov 16)

•	Sunesis to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
	Marketwire (Thu, Nov 12)

•	Sunesis to Present Nonclinical Voreloxin Combination Data at AACR-EORTC-NCI Conference
	PRNewswire (Tue, Nov 10)

•	Sunesis leukemia drug gets FDA orphan drug designation
	at bizjournals.com (Thu, Nov 5)

More Headlines for SNSS...

ANALYST

EPS Est (next year) (Dec-09) :	-2.08
EPS Est (in 2 years) (Dec-10) :	-0.62
Avg Rec (current)*:	1.7
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers.

Full Company Profile

Add to Portfolio

Email to a Friend

•